Novo Nordisk (NVO) said the European Commission granted marketing authorization for its once-daily oral semaglutide 25 mg (Wegovy) for adults with obesity or overweight with at least one weight-related comorbidity. This regulatory approval expands the company’s obesity treatment franchise beyond injectable therapy. The news is likely to be incremental but supportive for sentiment around future sales opportunities in Europe.
Novo Nordisk (NVO) said the European Commission granted marketing authorization for its once-daily oral semaglutide 25 mg (Wegovy) for adults with obesity or overweight with at least one weight-related comorbidity. This regulatory approval expands the company’s obesity treatment franchise beyond injectable therapy. The news is likely to be incremental but supportive for sentiment around future sales opportunities in Europe.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.50
Ticker Sentiment
